Amlapitta Mishran Shows Promise in Reducing Gastritis Symptoms and Endoscopic Scores
核心洞察
Amlapitta Mishran (搜索) significantly reduced endoscopy scores in patients with endoscopic gastritis (搜索) after 30 days of treatment, indicating a potential for healing stomach erosions.
The study demonstrated a statistically significant decrease in Amlapitta Symptom Rating Scale, Postprandial Distress Syndrome (搜索) (PPDS), and Epigastric Pain Syndrome (搜索) (EPS) scores.
Over 89% of participants experienced at least a 50% improvement in symptom scores related to gastritis (搜索), PPDS, and EPS after treatment with Amlapitta Mishran (搜索).
A prospective, single-center, open-label study reveals that Amlapitta Mishran (搜索), a multi-component Ayurvedic formulation, demonstrates efficacy in reducing both the symptoms and endoscopic markers of gastritis (搜索). The pilot study, published in Journal of Ayurveda and Integrative Medicine, suggests a potential role for Amlapitta Mishran in managing endoscopic gastritis.
The study enrolled 30 participants with endoscopic gastritis (搜索), administering Amlapitta Mishran (搜索) Suspension for 30 days. Endoscopic and symptomatic assessments were conducted at baseline and after the treatment period to evaluate the impact of the intervention. The primary efficacy endpoints included changes in endoscopy scores, Amlapitta Symptom Rating Scale scores, Postprandial Distress Syndrome (搜索) (PPDS) scores, and Epigastric Pain Syndrome (搜索) (EPS) scores.
Significant Symptom Reduction
Results indicated a statistically significant (P<0.05) reduction in endoscopy scores from baseline to the end of the study, as determined by Wilcoxon Signed Rank test. Specifically, 64% of participants achieved an endoscopy score of 1 (indicating no erosions) by the end of the 30-day treatment period. Furthermore, Amlapitta Symptom Rating Scale, PPDS, and EPS scores all exhibited significant reductions (P < 0.05) at both Visit 3 and Visit 4 compared to baseline, as shown by Friedman’s test with post hoc analysis.
Improvement in Symptom Scores
Clinically meaningful improvements were also observed, with 96% of participants experiencing at least a 50% reduction in Amlapitta Symptom Rating Scale scores, 89% showing a similar improvement in PPDS scores, and 93% reporting at least a 50% reduction in EPS scores. These findings suggest a substantial alleviation of gastritis (搜索)-related symptoms following treatment with Amlapitta Mishran (搜索).
Safety Profile
Safety was also a key focus of the study. Laboratory investigations conducted throughout the trial period revealed no significant abnormalities, indicating that Amlapitta Mishran (搜索) was well-tolerated by the participants. All safety variables remained within normal ranges across all visits.
The study's authors conclude that Amlapitta Mishran (搜索) holds promise as a therapeutic intervention for managing endoscopic gastritis (搜索), citing its ability to reduce both endoscopic scores and gastritis-related symptoms without significant adverse effects. However, they also acknowledge the limitations of the single-center, open-label design and call for larger, randomized controlled trials to confirm these findings and further elucidate the mechanisms of action of Amlapitta Mishran.